• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • recurrence-free survival
Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety
Posted inDermatology Oncology

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety

Posted by By MedXY 10/25/2025
The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.
Read More
  • Delayed Immunity to Streptococcus pyogenes and Respiratory Viruses in Young Children Following COVID-19 Restrictions: Implications for Recent Infection Surges
  • Declining Antiviral Prescribing for High-Risk Children with Influenza in US Pediatric Emergency Departments During the COVID-19 Era
  • Glucagon-Like Peptide-1 Receptor Agonists May Lower the Risk of Nonexudative Age-Related Macular Degeneration in Obese Non-Diabetic Adults
  • Early Diagnosis of Postpartum Haemorrhage: Insights from the E-MOTIVE Trial in Africa
  • Oral Manifestations of Lamellar Ichthyosis: A Case Report of Two Siblings
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk clinical trial COPD depression diabetes diet epidemiology exercise gut microbiota health heart failure Hypertension immunotherapy inflammation long-term outcomes mental health metformin Mortality multiple myeloma nutrition obesity older adults Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial sexual health targeted therapy treatment type 2 diabetes weight loss wellness women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in